Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors

/in

Seasoned executive with three decades of experience in pharma and biotech Biotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck) Appointment comes as Blue Cell looks to progress its lead candidate, allogeneic stem cell treatment BlueC-231, into Phase 1/2a clinical […]

Read more

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

/in

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events Enrolment is now open for the study, with initial data readout expected in 2026 Edinburgh and London, UK, 3 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a […]

Read more

ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump

/in

Led by new investor Innovation Industries, with matching contributions from existing investors, Partners in Equity and Invest-NL, the $85M round also drew support from EQT Life Sciences and Health Innovations, demonstrating strong confidence in ViCentra’s next phase of growth Fresh capital fuels scale-up, regulatory pathway, and commercialization of Kaleido 2, the world’s smallest, lightest, and […]

Read more

Novo Holdings co-leads Phasecraft’s $34 million Series B financing to bring quantum computing closer to solving real-world challenges

/in

New funding follows US expansion and will accelerate Phasecraft’s R&D to develop practical applications in collaboration with end users Phasecraft is developing algorithms that bridge the gap between today’s noisy quantum computers and tomorrow’s world-changing applications Copenhagen, Denmark, 2 September 2025 – Novo Holdings, a leading life science investor, today announced it has co-led the $34 […]

Read more

Advanced Medical Solutions Group plc – Notice of Interim Results

/in

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), a world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2025 on Wednesday 17 September 2025. Read more…

Read more
© Optimum Strategic Communications.